Coronavirus

ENA Respiratory Successfully Completes Phase Ib Dosing of Antiviral Host Defense Immune Enhancer INNA-051 Dry Powder Formulation in Older Adults and Advances Study in Young Adults

New intranasal formulation with significantly improved stability was well-tolerated and led to local activation of innate immune pathways in adults…

3 months ago

ISM Honors Manufacturing PMI® Outgoing Chair and Welcomes New Leader to Support Economic Reports

Timothy R. Fiore, Celebrated for His Exceptional Leadership, Retires from Role and Jeffrey P. Wincel Named as Incoming Chair TEMPE, Ariz.,…

3 months ago

Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT

FORT LAUDERDALE, FL / ACCESS Newswire / January 21, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company…

3 months ago

Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma

PDUFA action date of July 22, 2025, with priority reviewWOBURN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:…

3 months ago

XORTX Announces Change of Auditor

CALGARY, Alberta, Jan. 17, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX…

3 months ago

Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer

FORT LAUDERDALE, FL / ACCESSWIRE / January 15, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering…

3 months ago

Aptevo’s Peter Pavlik, PhD, Chairing Session on “Bi and Multispecific Biologics” at Cambridge Healthcare Institute’s Pep Talk 2025

Also giving an in-session talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR® Platform," showcasing Aptevo's drug engineering…

3 months ago

NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025

SHELTON, CT / ACCESSWIRE / January 13, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing…

3 months ago

Generate:Biomedicines Provides Update on its Platform and Pipeline Powered by AI at the 43rd Annual J.P. Morgan Healthcare Conference

SOMERVILLE, Mass., Jan. 9, 2025 /PRNewswire/ -- Generate:Biomedicines ("Generate") today announced that Mike Nally, Chief Executive Officer, will provide an…

3 months ago

Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals

SHELTON, CT / ACCESSWIRE / January 8, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE American: NNVC) (the…

3 months ago